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Anti-coagulation therapy following coronary 
endarterectomy in patient with coronary artery  
bypass graft 
 
Abstract 
Background: Since there is a lack of research on postoperative anticoagulation protocol in 
patients undergoing coronary artery bypass graft (CABG) / coronary endarterectomy (CE), 
we recommend a new protocol for anticoagulation in these patients. 
Methods: In this double-blind randomized clinical trial study, 52 patients undergoing 
CABG / CE entered the study and were divided into two groups. In group 1, the patients 
were given  warfarin(international normalized ratio (INR) between 2-3) together with 80 
mg aspirin daily for 3 months. In group 2, the patients were given 75 mg plavix daily 
together with 80 mg aspirin daily for 3 months. We evaluated patients with 
electrocardiography, echocardiography and checking ceratin phosphokinase MB and 
troponin I in the several stages. The data were analysed SPSS Version18 software. 
Results: There was no significant difference between pre and post-operative Ejection 
fraction in patients with plavix (P=0.21) and warfarin (P=0.316) regimen. However, wall 
mrotion score was significantly better in clopidogrel – aspirin patients in late (3 months) 
post operation (p<0.001). 
Conclusions: Since warfarin has serious hemorrhagic complications and requires closed 
monitoring of serum drug activity by serial INR checking, it is recommended that 
clopidogrel – aspirin can be the preferred alternative anticoagulation therapy in CABG / 
CE patients. 
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Full myocardial revascularization is the essential primary aim in the treatment of 
coronary artery disease (CAD) and is the most important factor that recognizes surgical 
revascularization from other forms of revascularization such as percutaneous coronary 
intervention (PCI) (1-3). Before presentation of coronary artery bypass grafting (CABG) 
as the gold standard in the surgical treatment of CAD, coronary endarterectomy (CE) was 
one of surgical techniques recommended for the management of complex coronary artery 
stenoses (4). Theoretically, combination of these two techniques (CABG/CE) can lead to 
more complete myocardial revascularization in complex CADs. This is especially 
important in patients with diffuse CAD, because they usually have limited available target 
vessels for CABG (5, 6). There are numerous reports that in early postoperative period, 
CABG/ CE  in comparison with isolated CABG puts the patients in poorer outcomes in 30-
days follow up (7, 8). Many efforts have been made to maintain patency of 
endarterectomized coronary grafts in postoperative period and to prevent such graft failure 
and subsequent perioperative myocardial infarction (MI) in that territory. Generally, as 
routine practice in patients with CABG / CE, it is recommended that warfarin in 
combination with aspirin should be continued until 3 months postoperatively and 
eventually aspirin alone permanently.    
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Warfarin therapy has some serious potential side effects 
such as bleeding, tissue necrosis and  hypersensitivity 
reactions .Thus ,patients must be evaluated weekly for 
International normalized ratio (INR) testing to keep it around 
2-3. On the other hand, several studies documented the 
combination of aspirin – clopidogrel as an effective 
treatment in acute MI (8, 9). So the combination of aspirin – 
clopidogrel has been recognized as gold standard treatment 
in acute coronary syndromes aiming inhibition of platelet 
aggregation. One of the benefits of clopidogrel is that there 
is no need to test INR once a week. Since there is a lack of 
research on postoperative anticoagulation protocol in 
patients with CABG / CE, we decided to conduct this study 
as a clinical trial to compare the outcomes in two such 
protocols: clopidogrel – aspirin and warfarin – aspirin. 
 
 
Methods 
This study was a randomized, double-blind, clinical trial 
performed at Ayatollah Rouhani Hospital, Babol, Iran. A 
total of 55 consecutive patients undergoing CABG / CE with 
cardiopulmonary bypass (CPB) from May 2012 to June 2014 
were evaluated. All patients gave an informed consent to 
enter the study. This study was approved by the Ethics 
Committee of Babol University of Medical Sciences 
(IRCT2016102730410N2). Exclusion criteria were as 
follows: a need to concomitant valve surgery, history of 
allergic reaction to medications used in the study  and any 
comorbidity (renal and hepatic failure, respiratory 
insufficiency).  
All patients underwent standard CABG / CE with CPB 
and the same technique of intermittent antegrade cold blood 
cardioplegia. In all cases, decision to endarterectomy was 
made if the lumen of coronary artery was occluded totally, 
seemingly that acceptable grafting would be impossible 
without endarterectomy. To perform an endarterectomy, 
target coronary artery was incised longitudinally 1.5 to 2.5 
centimeters along with atherosclerotic plaque which would 
be removed and then after “closed “endarterectomy by aid of 
a dissector, the plaque was excised with secure distal 
tapering. In postoperative period, the patients were divided 
into two groups randomly. In group “warfarin – aspirin “as 
routine practice in literature,  from the first postoperative 
day, aspirin was taken by the patients, in addition to warfarin 
to reach target range of  INR  2-3 days. In “clopidogrel -
aspirin “group, from first postoperative day, 80 mg aspirin 
was given to thepatients plus 75 mg clopidogrel. All data of 
both groups were collected and analyzed by a blinded 
cardiologist. These data included ECG (new Q wave and 
new ST-T changes) and cardiac enzymes (cardiac troponin I 
and CPK”MB”). These parameters serially checked intervals 
including just pre-and-post operation, after 24 hours and 48 
hours post operation. An echocardiography was also 
performed in all patients in preparation and 3 month post 
operation evaluating ejection fraction (EF) and wall motion 
abnormality. Wall motion abnormality was quantified by 
wall motion score index (WMSI). All 16 cardiac segments 
were evaluated in WMSI.Wall motion score will be 1 if wall 
motion is normal and it will be 2 if wall motion is 
hypokinetic. Wall motion score in akinetic wall or scar tissue 
was 3. The mean value of scores of all 16 cardiac segments 
is known as “total”WMSI but “local”WMSI  is the mean 
value of scores of segments of a special coronary artery 
territory. The statistical analysis software (Version 18, 
SPSS) was used for all analyses. All data were analysed 
using the chi – square test, Fisher‘s exact test and t- test. A 
p-value less than 0.05 was considered significant. 
 
 
Results 
From 55 patients with CABG / CE, 3 patients were 
excluded. 52 remaining patients were divided into two 
groups randomly. 31 patients were in clopidogrel – aspirin 
group (including 19 males and 12 females) while 21 patients 
were in warfarin – aspirin group (including 10 males and 11 
females) (figure1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1. Schematic representation of groups in study 
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The mean age in clopidogrel – aspirin group was 
62.9±9.85 years and in warfarin – aspirin group was 
58.86±11.42 years. This was not statistically significant. 
According to sex, there was no statistically significant 
difference between two groups. From all cases of 
endarterectomy, 19 (36.5%) cases were in left anterior 
descending (LAD) coronary artery (including 7 ones in 
warfarin group and 12 ones in clopidogrel group) and 33 
(63.5%) cases in the right coronary artery (RCA) (including 
14 cases in warfarin group and 19 cases in clopidogrel 
group). The mean ICU stay was 4.6±1.9 days in clopidogrel 
group and 4.63±1.29 days in warfarin group. This difference 
was not statistically significant (P=0.949). The mean hospital 
stay was 9.07±3.29 days in clopidogrel group and 9.26±1.93 
days in warfarin group (p=0.820). ECG was obtained 
immediately, 24h and 48h postoperation showed no new Q 
wave nor new ST-T changes in two groups of patients.  
Serum CPK(MB) level was checked for any association 
before surgery and immediately after surgery, in addition to 
24 and 48h later. With the attention to increase postoperative 
serum CPK (MB) level, the excess of more than five times 
greater preoperative value as the index of  perioperative MI, 
no patients in neither groups had perioperative MI. Pre and 
post operative echocardiographic study of EF showed no 
significant difference between the two groups nor in each 
group per se (table 1).  
 
Table1: Pre and postoperative echocardiographic data 
(ejection fraction and wall motion score index) in 
warfarin-aspirin and clopidogrel-aspirin groups. 
 
 Warfarin – 
aspirin 
Mean±SD 
Clopidogrel – 
aspirin 
Mean±SD 
Preoperative EF *  
Late postoperative EF 
42.63±10.97 
41.05±10.74 
42.76±7.97 
44.83±8.71 
P-value  0.316 0.212 
Preoperative WMSI **  
Postoperative WMSI 
1.88±0.47 
1.83±0.6 
2.01±0.47 
1.79±0.46 
P-value  0.477 0.001 
* EF: Ejection Fraction,    **WMSI: Wall motion score index 
 
As regards total heart WMSI to compare pre and 3 
months postoperation, a significant difference was seen in 
clopidogrel – aspirin group (p- value less than 0.001) but not 
in warfarin – aspirin group (table 1). The same result has 
been obtained about local heart WMSI in territory of LAD 
and RCA. In other words, in regard to local heart WMSI to 
compare pre and 3 months post operation, there was a 
significant difference in clopidogrel – aspirin group but not 
in warfarin – aspirin group.  
 
 
Discussion 
There are a few studies in literature evaluating  
anticoagulation protocol in post CABG / CE patients, 
therefore, we decided to compare two anticoagulation 
protocol (“platelet “ inhibitor and “factor “ inhibitor) in these 
patients. CE is a known surgical technique required in some 
CABG patients with severe and diffuse atherosclerotic 
coronary involvement.  
The main concern regarding in this technique is the 
patency rate of grafting to such vessels postoperatively. As 
routine practice, it is recommended that such patients should 
be anticoagulated with warfarin for at least 3 months 
postoperatively which is expected time for complete 
neoendothelialization of endarterectomized vessels. Since  
morbidity and sometimes mortality of “warfarin toxicity “ 
necessitates closed monitoring of drug serum activity with 
serial INR checking, an alternative anticoagulant can be 
considered if it would have same effect without such 
problems. This study aimed to show that whether the 
anticoagulative effects of anti platelet agents such as 
clopidogrel, could be sufficient for the prevention of 
thrombosis of endarterectomized vessels during the time 
required for neoendothelialization.  Principally, definitive 
evaluation of graft patency requires coronary catheterization 
directly, but generally it is not recommended if there is no 
clinical indication. Therefore in this study, we have 
employed indirect tools to evaluate graft patency. 
Postoperative ECG changes (new Q wave or new ST-T 
changes) in addition to increased serum CPK (MB) level 
(more than 5 times preoperative value) were considered as 
indicators of perioperative MI in early postoperative period. 
On the other hand, total or local WMSI in a special coronary 
artery territory was considered as such indicator in late (3 
months) postoperative period. Most studies of CE in the 
literature have compared CABG / CE patients with CABG 
alone. Some studies have evaluated outcomes of CABG / CE 
patients. As mentioned earlier, there are a few studies 
evaluating post CABG / CE anti coagulation protocol. Thus, 
we cannot compare this study to similar others properly.  
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Some studies evaluating post CABG / CE clinical course 
indicated that postoperative outcome in CABG patients with 
or without CE does not differ significantly (10). Hence, 
although patients requiring CE generally have higher cardiac 
risk profile and more severe coronary atherosclerotic 
involvement, CE is a preferred surgical option to obtain full 
myocardial revascularization. On the contrary, some other 
studies reported more mortality in patients with CABG / CE 
compared with CABG alone and consequently, it has been 
recommended that the addition of CE to CABG requires 
more caution (11). In our experience, CE was not 
accompanied with any graft thrombosis because there was no 
early nor late perioperative MI, so it seems that higher rate of 
morbidity and mortality of CABG / CE patients is related to 
more severe coronary artery atherosclerotic involvement of 
these patients due to higher cardiac risk profile and longer 
time coronary artery disease and CE per se is not the cause 
of increasing risk in such patients. In a study to consider late 
angiographic result of CABG / CE patients, it was shown 
that although adding warfarin to aspirin in postoperative 
anticoagulation therapy increases hemorrhagic risk, it is 
necessary to recommend it to maintain such patent graft, but 
this study did not compare warfarin to other drugs like 
clopidogrel (12). In another study, in the interim emphasis 
on lack of studies evaluating post CABG / CE 
anticoagulation protocol, two forms of management were 
carried out. In the first half of the study, patients were 
anticoagulated with warfarin – aspirin for 3 months post 
operation and then with aspirin alone. In the last half of the 
study, 3 months warfarin – aspirin was followed by 
clopidogrel – aspirin permanently. Since the design of the 
study was to evaluate early and late outcomes of CE in 
CABG / CE patients, it could not compare anti coagulation 
effects of two regimens warfarin – aspirin and clopidogrel – 
aspirin. This study concluded that because of disturbed 
endothelial integrity in endarterectomized vessels, aspirin 
alone could not maintain long-term such graft patency (13).
 
Yet  there is not enough evidence to assume that 
endothelial manipulation in CE is somewhat similar to 
endothelial changes that occur in some other conditions such 
as during percutaneous coronary intervention (PCI) or during 
acute coronary syndromes. There are numerous reports that 
showed such senarios aspirin alone is not sufficient and 
adding some other agents is necessary (14, 15). As routine 
practice, it is recommended that heparin in acute coronary 
syndromes, and clopidogrel in PCI patients should be added 
to aspirin. In CE patients, warfarin is routinely used along 
with aspirin, but in this study, clopidogrel was considered to 
compare two protocols: warfarin – aspirin and clopidogrel – 
aspirin. Since re–catheterization of patients in post operative 
period is not routinely recommended, evaluation of graft 
patency was limited to indirect evidence such as ECG 
changes, CPK (MB) levels and WMSI alterations. The 
primary aim of this study was to compare two 
anticoagulation protocols and warfarin is used until 3 months 
post operation routinely, as a result we decided to limit the 
study in this period of time. But we suggest complementary 
and future studies with larger sample size and longer follow-
up period beyond 3 months evaluating clopidogrel – aspirin 
compared with aspirin alone. 
In CABG / CE patients, graft patency rate in early post 
operative period is similar in two anticoagulation protocols 
warfarin and clopidogrel. In late ( 3 months)postoperation, 
WMSI was significantly better in clopidogrel patients;  so 
warfarin in spite of clopidogrel has serious hemorrhagic 
complications and requires close monitoring of serum drug 
activity with serial INR checking,  it is suggested that 
clopidogrel – aspirin can be a preferred alternative 
anticoagulation therapy in CABG / CE patients.  
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